MANHASSET, NY–(BUSINESS WIRE)–Nov. 15, 2022–
As the coronavirus disease 2019 (COVID-19) pandemic gripped the country, doctors struggled to keep up with the ever-changing and unpredictable outlook of their patients. Scientists at the Feinstein Institutes for Medical Research saw early potential in using diverse patient population data from Northwell Health – New York’s largest healthcare system – and developed a clinical tool to better inform the front-line staff about a patient’s prognosis and disease severity. J two and a half years later, pulling from 35,000 hospitalized COVID-19 patients, researchers have published results inNature Communication detailing how data from basic blood tests and other vital signs could accurately project a patient’s outcome and aid in clinical care decision-making.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20221115006164/en/
Dr. Theo Zanos led the research that created a self-monitoring, self-updating artificial intelligence (AI) model clinical support tool. (Credit: Feinstein Institutes)
The research, led by Theo Zanos, PhD, associate professor at the Feinstein Institutes Institute of Health System Sciences and Institute of Bioelectronic Medicine, accounted for rapid changes in patient status and outcomes across different waves of COVID-19 and the variants that caused them, alongside the emergence of vaccines and treatments, and created a self-monitoring and self-updating artificial intelligence (AI) model clinical support tool . Dr. Zanos and his lab analyzed electronic health record (EHR) data from hospitalized patients at 13 Northwell Health hospitals between April 2020 and May 2022.
“COVID-19 was one of the most dynamic diseases we have seen in modern history and information about how to care for patients was constantly evolving,” said Dr. Zanos, lead author of the paper. . “By leveraging the data and developing a clinical tool that automatically updates in real time, we set out to create a tool that takes these developments into account and helps clinicians make the decisions they need to provide better care. .”
Current predictive models for COVID-19 patients do not account for real-time changes in patient characteristics and outcomes. In Dr. Zanos’ new model, the proposed framework continuously monitors predictive performance and is automatically updated when it detects performance drifts. This framework was crucial in providing clinicians with accurate predictions for 28-day survival of COVID-19 patients at all stages of the pandemic and can be similarly applied to other dynamic diseases.
The model uses only five early and commonly collected data points from patients during hospitalization; age, serum urea nitrogen, lactate, serum albumin and red blood cell distribution width. The pattern remained accurate throughout the over two-year study, occurring across four waves and three dominant variants (Alpha, Delta, and Omicron) and functioning the same regardless of race, ethnicity and sex.
“This important study leveraged data analysis and technology to develop new insights into a novel disease,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Distinguished Chair of the Karches family in medical research. “Dr. Zanos’ strategy provides a new model for studying COVID-19 as a guide to clinical decision-making and better outcomes.
In addition to the published study that details the validation and construction techniques of the tool, the team provides the medical and scientific community with the open-source code of the framework, the clinical data used to derive these models, as well as ‘a calculator (mlmd.org/nocos) that allows users to enter information and view the functionality of the tool.
The Feinstein Institutes continue to lead the study of AI and machine learning clinical support tools. More recently, researchers unveiled a new digital tool that assesses and lowers the risk of patients with blood clots – many of whom suffered from Covid-19, both during and after discharge from hospital during a presentation last-minute clinical trial to the American Heart Association. Scientific Sessions 2022.
About the Feinstein Institutes
The Feinstein Institutes for Medical Researchis home to the research institutes of Northwell Health, New York State’s largest health care provider and private employer. Encompassing 50 research laboratories, 3,000 clinical research studies, and 5,000 researchers and staff, the Feinstein Institutes elevate the level of medical innovation through its five institutes of behavioral sciences, bioelectronic medicine, cancer, health system sciences and molecular medicine. We’re making breakthroughs in genetics, oncology, brain research, mental health and autoimmunity, and we’re the world’s scientific leader in bioelectronic medicine, a new field scientist who has the potential to revolutionize medicine. For more information on how we produce knowledge to cure disease, visithttp://feinstein.northwell.eduand follow us onLinkedIn.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221115006164/en/
CONTACT: Matthieu Libassi
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SOFTWARE RESEARCH DATA MANAGEMENT BIOMETRY TECHNOLOGY INFECTIOUS DISEASES HOSPITALS ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY HEALTH
SOURCE: The Feinstein Institutes for Medical Research
Copyright BusinessWire 2022.
PUBLISHED: 11/15/2022 11:13 AM/DISC: 11/15/2022 11:13 AM
Copyright BusinessWire 2022.
#digital #tool #predicts #prognosis #Covid19 #patient